8.55
price down icon7.37%   -0.68
after-market After Hours: 8.55
loading
Seres Therapeutics Inc stock is traded at $8.55, with a volume of 83,048. It is down -7.37% in the last 24 hours and down -33.20% over the past month. Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
See More
Previous Close:
$9.23
Open:
$9.1
24h Volume:
83,048
Relative Volume:
1.22
Market Cap:
$81.95M
Revenue:
$123.24M
Net Income/Loss:
$136.00K
P/E Ratio:
-427.50
EPS:
-0.02
Net Cash Flow:
$-148.99M
1W Performance:
-9.04%
1M Performance:
-33.20%
6M Performance:
-43.39%
1Y Performance:
-64.08%
1-Day Range:
Value
$8.50
$9.10
1-Week Range:
Value
$8.50
$10.12
52-Week Range:
Value
$7.179
$30.60

Seres Therapeutics Inc Stock (MCRB) Company Profile

Name
Name
Seres Therapeutics Inc
Name
Phone
617 945 9626
Name
Address
200 SIDNEY STREET, CAMBRIDGE, MA
Name
Employee
103
Name
Twitter
@SeresTX
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
MCRB's Discussions on Twitter

Compare MCRB with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
MCRB
Seres Therapeutics Inc
8.55 81.95M 123.24M 136.00K -148.99M -0.02
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.03 129.44B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.52 61.42B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
615.11 38.44B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
269.81 33.29B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
241.75 26.95B 3.81B -644.79M -669.77M -6.24

Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-24-24 Downgrade JP Morgan Neutral → Underweight
Jun-26-23 Resumed Oppenheimer Outperform
Apr-21-23 Initiated JP Morgan Neutral
Jul-23-21 Downgrade Goldman Neutral → Sell
May-18-21 Resumed Goldman Neutral
Mar-05-21 Upgrade Chardan Capital Markets Neutral → Buy
Sep-18-20 Downgrade Chardan Capital Markets Buy → Neutral
Aug-18-20 Initiated Piper Sandler Overweight
Aug-11-20 Reiterated H.C. Wainwright Buy
Aug-11-20 Upgrade Jefferies Hold → Buy
Apr-30-19 Initiated Jefferies Hold
Oct-22-18 Initiated Chardan Capital Markets Buy
Oct-13-17 Initiated Oppenheimer Outperform
Aug-04-17 Reiterated H.C. Wainwright Buy
Feb-01-17 Reiterated FBR & Co. Outperform
Aug-12-16 Reiterated FBR Capital Outperform
Aug-01-16 Downgrade BofA/Merrill Buy → Neutral
Aug-01-16 Reiterated H.C. Wainwright Buy
Jul-29-16 Resumed H.C. Wainwright Buy
Mar-30-16 Initiated FBR Capital Outperform
Mar-03-16 Initiated Guggenheim Buy
Jan-25-16 Initiated H.C. Wainwright Buy
Oct-22-15 Upgrade BofA/Merrill Neutral → Buy
Jul-22-15 Initiated Canaccord Genuity Buy
Jul-21-15 Initiated Goldman Neutral
Jul-21-15 Initiated Leerink Partners Outperform
View All

Seres Therapeutics Inc Stock (MCRB) Latest News

pulisher
May 06, 2025

Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025 - The Globe and Mail

May 06, 2025
pulisher
May 06, 2025

Analysts Set Seres Therapeutics, Inc. (NASDAQ:MCRB) PT at $80.00 - Defense World

May 06, 2025
pulisher
May 05, 2025

Seres Therapeutics Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView

May 05, 2025
pulisher
May 01, 2025

Seres Therapeutics (NASDAQ:MCRB) Cut to Sell at StockNews.com - Defense World

May 01, 2025
pulisher
Apr 29, 2025

Seres Therapeutics Reveals Game-Changing Biomarkers for IBD Treatment, Seeks Development Partners - Stock Titan

Apr 29, 2025
pulisher
Apr 29, 2025

Seres Therapeutics (MCRB) to Unveil New Findings at 2025 Digesti - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases - The Manila Times

Apr 29, 2025
pulisher
Apr 28, 2025

Investor’s Delight: Seres Therapeutics Inc (MCRB) Closes Weak at 0.70, Down -2.90 - DWinneX

Apr 28, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 25, 2025

Seres Therapeutics (NASDAQ:MCRB) Raised to Hold at StockNews.com - Defense World

Apr 25, 2025
pulisher
Apr 24, 2025

MCRB Stock Update: Seres Therapeutics Inc’s Banking’s Market Struggles and Potential Opportunities - investchronicle.com

Apr 24, 2025
pulisher
Apr 24, 2025

Seres Therapeutics Inc (MCRB) expanding its growth trajectory ahead - Sete News

Apr 24, 2025
pulisher
Apr 23, 2025

Seres Therapeutics Reveals Q1 2025 Results: Live Biotherapeutics Pioneer Updates Growth Strategy - Stock Titan

Apr 23, 2025
pulisher
Apr 23, 2025

Seres Therapeutics enacts 1-for-20 reverse stock split By Investing.com - Investing.com India

Apr 23, 2025
pulisher
Apr 22, 2025

Seres Therapeutics enacts 1-for-20 reverse stock split - Investing.com

Apr 22, 2025
pulisher
Apr 22, 2025

JP Morgan downgrades Seres Therapeutics Inc (MCRB) rating to an Underweight - knoxdaily.com

Apr 22, 2025
pulisher
Apr 21, 2025

Oppenheimer Adjusts Seres Therapeutics Price Target to $5 From $9, Maintains Outperform Rating - marketscreener.com

Apr 21, 2025
pulisher
Apr 21, 2025

Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023 - marketscreener.com

Apr 21, 2025
pulisher
Apr 21, 2025

Upcoming Stock Splits This Week (April 21 to April 25) – Stay Invested - The Globe and Mail

Apr 21, 2025
pulisher
Apr 17, 2025

Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a Turnaround - NewsBreak: Local News & Alerts

Apr 17, 2025
pulisher
Apr 16, 2025

MCRB stock touches 52-week low at $0.46 amid market challenges By Investing.com - Investing.com South Africa

Apr 16, 2025
pulisher
Apr 16, 2025

MCRB stock touches 52-week low at $0.46 amid market challenges - Investing.com

Apr 16, 2025
pulisher
Apr 14, 2025

Seres Therapeutics enacts stock incentive plan and reverse split By Investing.com - Investing.com South Africa

Apr 14, 2025
pulisher
Apr 14, 2025

12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga

Apr 14, 2025
pulisher
Apr 14, 2025

Seres Therapeutics enacts stock incentive plan and reverse split - Investing.com

Apr 14, 2025
pulisher
Apr 14, 2025

Seres Therapeutics Approves Reverse Stock Split Plan - TipRanks

Apr 14, 2025
pulisher
Apr 12, 2025

Seres Therapeutics (NASDAQ:MCRB) Rating Lowered to Sell at StockNews.com - Defense World

Apr 12, 2025
pulisher
Apr 11, 2025

Seres Therapeutics Inc (NASDAQ: MCRB): Blank Check On Growth? - stocksregister.com

Apr 11, 2025
pulisher
Apr 11, 2025

Analysts Set Seres Therapeutics, Inc. (NASDAQ:MCRB) Price Target at $4.00 - Defense World

Apr 11, 2025
pulisher
Apr 09, 2025

Strategic Power Move: Kymera Lands M&A Expert to Accelerate Drug Development Deals - Stock Titan

Apr 09, 2025
pulisher
Apr 08, 2025

MCRB stock touches 52-week low at $0.54 amid market challenges - Investing.com Australia

Apr 08, 2025
pulisher
Apr 08, 2025

MCRB stock touches 52-week low at $0.54 amid market challenges By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 03, 2025

INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding Possible Violations of Federal Securities Laws by Certain Officers and Directors of Seres Therapeutics, Inc.MCRB - ACCESS Newswire

Apr 03, 2025
pulisher
Apr 02, 2025

5 Best Microbiome Companies (May 2025) - Securities.io

Apr 02, 2025
pulisher
Apr 01, 2025

Charles Schwab Investment Management Inc. Purchases 117,107 Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World

Apr 01, 2025
pulisher
Mar 28, 2025

FY2025 Earnings Forecast for MCRB Issued By Chardan Capital - Defense World

Mar 28, 2025
pulisher
Mar 28, 2025

Avantax Advisory Services Inc. Increases Stake in Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World

Mar 28, 2025
pulisher
Mar 23, 2025

Seres Therapeutics (NASDAQ:MCRB) Given "Buy" Rating at Chardan Capital - MarketBeat

Mar 23, 2025
pulisher
Mar 22, 2025

Chardan Capital Reiterates Buy Rating for Seres Therapeutics (NASDAQ:MCRB) - Defense World

Mar 22, 2025
pulisher
Mar 21, 2025

Microbiome Disease Pipeline Insight 2025: Over 180 Drugs in Development Across 140+ Companies - GlobeNewswire Inc.

Mar 21, 2025
pulisher
Mar 20, 2025

Petri Dish: Flagship spinout Ampersand raises $65M, Seres medical chief lands new role - The Business Journals

Mar 20, 2025
pulisher
Mar 17, 2025

Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives $4.00 Consensus Target Price from Brokerages - Defense World

Mar 17, 2025
pulisher
Mar 16, 2025

The Goldman Sachs Group Issues Pessimistic Forecast for Seres Therapeutics (NASDAQ:MCRB) Stock Price - Defense World

Mar 16, 2025

Seres Therapeutics Inc Stock (MCRB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.42
price down icon 5.24%
$67.87
price down icon 6.49%
$32.11
price down icon 2.70%
$24.20
price down icon 13.63%
$94.74
price down icon 6.29%
biotechnology ONC
$241.75
price down icon 4.88%
Cap:     |  Volume (24h):